Please login to the form below

Not currently logged in
Email:
Password:

BioAlliance announces managerial changes

Dr Gilles Avenard resigns as board member and deputy CEO in charge of R&D, while Dr Pierre Attali becomes CEO

BioAlliance Pharma, a company dedicated to the supportive care and treatment of cancer patients, has announced changes to its management structure.

Dr Gilles Avenard has resigned as board member and deputy CEO in charge of R&D, while Dr Pierre Attali, who has been serving BioAlliance Pharma as chief medical officer for several years, has been appointed as the company's CEO.

Dominique Costantini, CEO of BioAlliance Pharma commented: "I am delighted by Pierre Attali's appointment. His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the company and its commercial partners when preparing the next launches of BioAlliance's products."

4th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics